135 related articles for article (PubMed ID: 7510813)
1. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation.
Gisselbrecht C; Prentice HG; Bacigalupo A; Biron P; Milpied N; Rubie H; Cunningham D; Legros M; Pico JL; Linch DC
Lancet; 1994 Mar; 343(8899):696-700. PubMed ID: 7510813
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
Gisselbrecht C; Haioun C; Lepage E; Bastion Y; Tilly H; Bosly A; Dupriez B; Marit G; Herbrecht R; Deconinck E; Marolleau JP; Yver A; Dabouz-Harrouche F; Coiffier B; Reyes F
Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
[TBL] [Abstract][Full Text] [Related]
3. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
Seymour AM; de Campos E; Thatcher N; De Greve J; Cunningham D; Howell A; Tueni E; Bron DG; Steward WP; Berdel WE
Eur J Cancer; 1995 Dec; 31A(13-14):2157-63. PubMed ID: 8652235
[TBL] [Abstract][Full Text] [Related]
4. Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.
Keating GM
Drugs; 2011 Apr; 71(6):679-707. PubMed ID: 21504247
[TBL] [Abstract][Full Text] [Related]
5. Effect of lenograstim on the cost of autologous bone marrow transplantation. A preliminary communication.
Brice P; Godin S; Libert O; Marolleau JP; Makki J; Extra JM; Faure P; Gisselbrecht C
Pharmacoeconomics; 1995 Mar; 7(3):238-41. PubMed ID: 10155313
[TBL] [Abstract][Full Text] [Related]
6. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
Frampton JE; Yarker YE; Goa KL
Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
[TBL] [Abstract][Full Text] [Related]
7. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.
Dunn CJ; Goa KL
Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839
[TBL] [Abstract][Full Text] [Related]
8. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.
Dombret H; Chastang C; Fenaux P; Reiffers J; Bordessoule D; Bouabdallah R; Mandelli F; Ferrant A; Auzanneau G; Tilly H
N Engl J Med; 1995 Jun; 332(25):1678-83. PubMed ID: 7539109
[TBL] [Abstract][Full Text] [Related]
9. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Bradstock K; Matthews J; Young G; Lowenthal R; Baxter H; Arthur C; Bashford J; Brighton T; Cannell P; Dunlop L; Durrant S; Enno A; Eliadis P; Gill D; Gillett A; Gottlieb D; Januszewicz H; Joshua D; Leahy M; Schwarer A; Taylor K;
Leukemia; 2001 Sep; 15(9):1331-8. PubMed ID: 11516093
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.
SouĂȘtre E; Qing W
Pharmacoeconomics; 1994; 6 Suppl 2():36-43. PubMed ID: 10172484
[TBL] [Abstract][Full Text] [Related]
11. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial.
Schmitz N; Ljungman P; Cordonnier C; Kempf C; Linkesch W; Alegre A; Solano C; Simonsson B; Sonnen R; Diehl V; Fischer T; Caballero D; Littlewood T; Noppeney R; Schafhausen P; Jost L; Delabarre F; Marcus R
Bone Marrow Transplant; 2004 Dec; 34(11):955-62. PubMed ID: 15489865
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia.
Takeshita A; Saito H; Toyama K; Horiuchi A; Kuriya S; Furusawa S; Tsuruoka N; Takiguchi T; Matsuda T; Utsumi M; Shiku H; Matsui T; Egami K; Tamura K; Ohno R
Int J Hematol; 2000 Feb; 71(2):136-43. PubMed ID: 10745623
[TBL] [Abstract][Full Text] [Related]
13. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
Locatelli F; Pession A; Zecca M; Bonetti F; Prete L; CarrĂ AM; Prete A; Montagna D; Comoli P; Taibi RM; Paolucci G
Bone Marrow Transplant; 1996 Jan; 17(1):31-7. PubMed ID: 8673051
[TBL] [Abstract][Full Text] [Related]
14. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Demuynck HM; Link H; Zander A; Barge A
Lancet; 1996 Feb; 347(8998):353-7. PubMed ID: 8598700
[TBL] [Abstract][Full Text] [Related]
15. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.
Nemunaitis J; Rabinowe SN; Singer JW; Bierman PJ; Vose JM; Freedman AS; Onetto N; Gillis S; Oette D; Gold M
N Engl J Med; 1991 Jun; 324(25):1773-8. PubMed ID: 1903847
[TBL] [Abstract][Full Text] [Related]
16. A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children. Lenograstim Study Group.
Donadieu J; Boutard P; Bernatowska E; Tchernia G; Couillaud G; Philippe N; Le Gall E
Eur J Pediatr; 1997 Sep; 156(9):693-700. PubMed ID: 9296532
[TBL] [Abstract][Full Text] [Related]
17. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
Kim IH; Park SK; Suh OK; Oh JM
Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefits of lenograstim in patients with neutropenia due to chemotherapy for multiple myeloma (MM).
Takagi T; Sawamura M; Sezaki T; Kashimura M; Tsuchiya J; Hotta T; Ogawa N; Hirashima K
Support Care Cancer; 2001 Jul; 9(5):397-9. PubMed ID: 11497396
[TBL] [Abstract][Full Text] [Related]
19. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia.
Gluckman E; Rokicka-Milewska R; Hann I; Nikiforakis E; Tavakoli F; Cohen-Scali S; Bacigalupo A;
Br J Haematol; 2002 Dec; 119(4):1075-82. PubMed ID: 12472591
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]